TAKE Solutions Limited (TAKE.NS)
INR 8.67
(2.0%)
INR 8.67
(2.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 183.42 Million INR | -82.71% |
| 2022 | 1.06 Billion INR | -77.0% |
| 2021 | 4.61 Billion INR | -21.3% |
| 2020 | 5.85 Billion INR | -62.23% |
| 2019 | 15.51 Billion INR | 5.89% |
| 2018 | 14.65 Billion INR | 29.58% |
| 2017 | 11.3 Billion INR | 99.69% |
| 2016 | 5.66 Billion INR | 24.47% |
| 2015 | 4.54 Billion INR | 41.64% |
| 2014 | 3.21 Billion INR | -42.86% |
| 2013 | 5.62 Billion INR | -0.96% |
| 2012 | 5.67 Billion INR | 23.67% |
| 2011 | 4.58 Billion INR | 137.32% |
| 2010 | 1.93 Billion INR | 66.18% |
| 2009 | 1.16 Billion INR | -3.79% |
| 2008 | 1.2 Billion INR | 15.6% |
| 2007 | 1.04 Billion INR | 62.57% |
| 2006 | 643.48 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 Q3 | 54.85 Million INR | -54.64% |
| 2023 Q4 | 39.39 Million INR | -28.19% |
| 2023 FY | 183.42 Million INR | -82.71% |
| 2023 Q1 | 92.61 Million INR | -37.89% |
| 2023 Q2 | 120.91 Million INR | 30.56% |
| 2022 Q4 | 149.09 Million INR | -53.84% |
| 2022 FY | 1.06 Billion INR | -77.0% |
| 2022 Q2 | 227.02 Million INR | -37.19% |
| 2022 Q3 | 323.03 Million INR | 42.29% |
| 2022 Q1 | 361.44 Million INR | 72.79% |
| 2021 Q3 | 1.45 Billion INR | 0.21% |
| 2021 Q4 | 209.17 Million INR | -85.67% |
| 2021 FY | 4.61 Billion INR | -21.3% |
| 2021 Q2 | 1.45 Billion INR | -1.92% |
| 2021 Q1 | 1.48 Billion INR | -13.66% |
| 2020 Q2 | 1.37 Billion INR | 21.22% |
| 2020 Q3 | 1.62 Billion INR | 18.15% |
| 2020 Q4 | 1.72 Billion INR | 5.78% |
| 2020 FY | 5.85 Billion INR | -62.23% |
| 2020 Q1 | 1.13 Billion INR | -49.1% |
| 2019 Q4 | 2.23 Billion INR | -52.89% |
| 2019 Q2 | 4.35 Billion INR | 3.79% |
| 2019 Q1 | 4.19 Billion INR | 9.2% |
| 2019 FY | 15.51 Billion INR | 5.89% |
| 2019 Q3 | 4.73 Billion INR | 8.82% |
| 2018 Q1 | 3.32 Billion INR | 2.69% |
| 2018 Q3 | 3.77 Billion INR | 1.51% |
| 2018 Q4 | 3.84 Billion INR | 1.84% |
| 2018 FY | 14.65 Billion INR | 29.58% |
| 2018 Q2 | 3.71 Billion INR | 11.73% |
| 2017 Q4 | 3.23 Billion INR | 11.26% |
| 2017 FY | 11.3 Billion INR | 99.69% |
| 2017 Q3 | 2.9 Billion INR | 8.83% |
| 2017 Q2 | 2.67 Billion INR | 7.58% |
| 2017 Q1 | 2.48 Billion INR | -1.12% |
| 2016 FY | 5.66 Billion INR | 24.47% |
| 2016 Q1 | 1.31 Billion INR | -40.75% |
| 2016 Q2 | 1.36 Billion INR | 3.7% |
| 2016 Q3 | 2.42 Billion INR | 77.37% |
| 2016 Q4 | 2.51 Billion INR | 3.72% |
| 2015 Q4 | 2.22 Billion INR | 103.26% |
| 2015 FY | 4.54 Billion INR | 41.64% |
| 2015 Q3 | 1.09 Billion INR | -36.64% |
| 2015 Q2 | 1.72 Billion INR | 70.44% |
| 2015 Q1 | 1.01 Billion INR | 3.9% |
| 2014 Q2 | 1.25 Billion INR | 78.76% |
| 2014 Q1 | 702.07 Million INR | -49.38% |
| 2014 FY | 3.21 Billion INR | -42.86% |
| 2014 Q4 | 974.96 Million INR | 19.65% |
| 2014 Q3 | 814.87 Million INR | -35.07% |
| 2013 Q1 | 1.38 Billion INR | 0.55% |
| 2013 Q2 | 1.46 Billion INR | 5.61% |
| 2013 Q3 | 1.39 Billion INR | -4.76% |
| 2013 FY | 5.62 Billion INR | -0.96% |
| 2013 Q4 | 1.38 Billion INR | -0.28% |
| 2012 Q1 | 1.45 Billion INR | 17.4% |
| 2012 Q2 | 1.42 Billion INR | -1.66% |
| 2012 FY | 5.67 Billion INR | 23.67% |
| 2012 Q4 | 1.37 Billion INR | -3.0% |
| 2012 Q3 | 1.41 Billion INR | -0.78% |
| 2011 Q3 | 1.15 Billion INR | 4.82% |
| 2011 FY | 4.58 Billion INR | 137.32% |
| 2011 Q2 | 1.1 Billion INR | 0.0% |
| 2011 Q4 | 1.23 Billion INR | 7.33% |
| 2010 FY | 1.93 Billion INR | 66.18% |
| 2009 FY | 1.16 Billion INR | -3.79% |
| 2008 FY | 1.2 Billion INR | 15.6% |
| 2007 FY | 1.04 Billion INR | 62.57% |
| 2006 FY | 643.48 Million INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Biocon Limited | 91.73 Billion INR | 99.8% |
| Blue Jet Healthcare Limited | 3.15 Billion INR | 94.194% |
| Concord Biotech Limited | 7.56 Billion INR | 97.575% |
| Dishman Carbogen Amcis Limited | 4.9 Billion INR | 96.26% |
| Jubilant Ingrevia Limited | 9.16 Billion INR | 97.999% |
| Lyka Labs Limited | 145.95 Million INR | -25.671% |
| Panacea Biotec Limited | 1.42 Billion INR | 87.153% |
| Piramal Pharma Limited | 24.47 Billion INR | 99.25% |
| SMS Lifesciences India Limited | 329.57 Million INR | 44.347% |
| Supriya Lifescience Limited | 2.65 Billion INR | 93.083% |
| Syngene International Limited | 12.43 Billion INR | 98.525% |
| Zota Health Care Limited | 332.52 Million INR | 44.841% |